硫代硫酸金鈉

硫代硫酸金鈉
臨床資料
給藥途徑	肌肉注射
ATC碼	M01CB02 (WHO) ;
識別資訊
	IUPAC命名法 trisodium dithiosulphate aurate(I), dihydrate; ;
CAS號	15283-45-1
PubChem CID	170028;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID90939916 ;
化學資訊
化學式	AuNa3O6S4
摩爾質量	490.17 g·mol−1

硫代硫酸金鈉（英語：Sodium aurothiosulfate）是化學式為Na₃Au(S₂O₃)₂·2H₂O的無機化合物，其陰離子是由一個金原子和二個硫代硫酸根離子配位而成的直線形離子^[1]^[2]。硫代硫酸金鈉和其他的金化合物一樣，可以做為抗風濕藥（英語：Antirheumatic）^[3]。第一次的安慰劑對照實驗可能是在1931年開始的，當時用sanocrysin治療結核病，以蒸餾水安慰劑比較其效果^[4]。

製備

硫代硫酸金鈉可由硫代硫酸鈉還原氯化金產生：^[5]

4 Na
2S
2O
3 + AuCl
3 → Na
3[Au(S
2O
3)
2] + Na
2S
4O
6 + 3 NaCl

結構

Na
3[Au(S
2O
3)
2] · 2H₂O在X射線晶體學下的結構。紅色：氧、橘色：金、黃色：硫、紫色：鈉。氫原子省略不畫

其離子錯合物的結構是線性的AuS2中心，整體是中心對稱結構。和其他過渡金屬硫代硫酸鹽（英語：thiosulfate complex）類似，硫代硫酸根中只有部份planetary的硫原子會和金屬配位^[6]^[7]^[5]。

參考資料

^ Baggio, R. Crystal and molecular structure of trisodium dithiosulphate aurate(I), dihydrate, Na3[Au(S2O3)2],2H2O. Journal of Inorganic and Nuclear Chemistry. 1973, 35 (9): 3191. doi:10.1016/0022-1902(73)80019-3.
^ Tobön-Zapata, G. Vibrational spectrum of Sanocrysin. Spectrochimica Acta Part a Molecular and Biomolecular Spectroscopy. 1997, 53 (2): 183. doi:10.1016/S1386-1425(97)83024-7.
^ Shaw, III, C. F. Gold-Based Therapeutic Agents. Chemical Reviews. 1999, 99 (9): 2589–600. PMID 11749494. doi:10.1021/cr980431o.
^ Ethical and regulatory aspects of clinical research: readings and commentary, Ezekiel J. Emanuel, Johns Hopkins University Press, 2003, p 140
^ ^5.0 ^5.1 Ruben, Helena.; Zalkin, Allan.; Faltens, Marjorie O.; Templeton, David H. Crystal structure of sodium gold(I) thiosulfate dihydrate, Na3Au(S2O3)2.2H2O. Inorganic Chemistry. 1974, 13 (8): 1836–1839. doi:10.1021/ic50138a011.
^ Baggio RF, Baggio S. Crystal and molecular structure of trisodium dithiosulphate aurate(I), dihydrate, Na₃[Au(S₂O₃)₂],2H₂O. Journal of Inorganic and Nuclear Chemistry. 1973, 35 (9): 3191–3200. doi:10.1016/0022-1902(73)80019-3.
^ Tobön-Zapata G, Etcheverry SB, Baran EJ. Vibrational spectrum of Sanocrysin. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 1997, 53 (2): 183–188. Bibcode:1997AcSpA..53..183T. doi:10.1016/S1386-1425(97)83024-7.

[1] Baggio, R. Crystal and molecular structure of trisodium dithiosulphate aurate(I), dihydrate, Na3[Au(S2O3)2],2H2O. Journal of Inorganic and Nuclear Chemistry. 1973, 35 (9): 3191. doi:10.1016/0022-1902(73)80019-3.

[2] Tobön-Zapata, G. Vibrational spectrum of Sanocrysin. Spectrochimica Acta Part a Molecular and Biomolecular Spectroscopy. 1997, 53 (2): 183. doi:10.1016/S1386-1425(97)83024-7.

[shaw-3] Shaw, III, C. F. Gold-Based Therapeutic Agents. Chemical Reviews. 1999, 99 (9): 2589–600. PMID 11749494. doi:10.1021/cr980431o.

[4] Ethical and regulatory aspects of clinical research: readings and commentary, Ezekiel J. Emanuel, Johns Hopkins University Press, 2003, p 140

[Zalkin-5] 5.0 ^5.1 Ruben, Helena.; Zalkin, Allan.; Faltens, Marjorie O.; Templeton, David H. Crystal structure of sodium gold(I) thiosulfate dihydrate, Na3Au(S2O3)2.2H2O. Inorganic Chemistry. 1974, 13 (8): 1836–1839. doi:10.1021/ic50138a011.

[6] Baggio RF, Baggio S. Crystal and molecular structure of trisodium dithiosulphate aurate(I), dihydrate, Na₃[Au(S₂O₃)₂],2H₂O. Journal of Inorganic and Nuclear Chemistry. 1973, 35 (9): 3191–3200. doi:10.1016/0022-1902(73)80019-3.

[7] Tobön-Zapata G, Etcheverry SB, Baran EJ. Vibrational spectrum of Sanocrysin. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 1997, 53 (2): 183–188. Bibcode:1997AcSpA..53..183T. doi:10.1016/S1386-1425(97)83024-7.

[1]

[2]

[3]

[4]

[5]

[6]

[7]